Global Exosomes Market - 2020-2027
|外排體的全球市場：2020-2027 Global Exosomes Market - 2020-2027|
|出版日期: 按訂單生產||內容資訊: 英文||
Exosomes are small membrane vesicles of endocytic origin that are secreted by most cells in culture, and are created upon the fusion of the multivesicular body (MVB), an intermediate endocytic compartment, with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. Exosomes are secreted via exocytosis by a variety of cell types, including cancer cells, and subsequently are taken up by target cells, where they communicate information via surface protein signaling as well as through the transfer of lipids, nucleic acids, and other biomolecules. Intercellular communication by exosomes plays a critical role in the regulation of cellular and physiological processes
Exosomes extracted from cow milk is being used for the delivery of therapeutic molecules against lung and breast cancers. Exosomes derived from specific sites of the body are promising candidates for anti-cancer vaccines, due to the enhanced passive targeting, owing to its small size, indigenous nature, and the ability to cross the biological barriers. Thus, the increase in the cancer cases in the hospitals directly increases the demand for exosomes in diagnosis as well as therapeutics.
The market is driven is the increasing prevalence of cancer, technological advancements in exosomes isolation and analytical procedures, and increasing advanced applications of exosomes. The growing prevalence of cancer patients has a direct impact on the increased demand for the exosomes market.
According to the 2012 report of the World Health Organization (WHO), there were 14 million new cases of cancer, and this is expected to rise by about 70% over the next two decades. In the United States, as per the National Cancer Institute report of 2018, an estimated 1.7 million new cases of cancer were diagnosed in the country and nearly 0.6 million patients died due to cancer. This factor will drive the growth of market in the forecast period.
Exosomes are of special interest in the field of medicine. Their ability to stimulate immune responses, for instance, has made them of particular interest in the development of novel approaches to vaccination, including the development of vaccines to treat certain cancers. In addition, because exosomes are found in body fluids such as blood, urine, and cerebrospinal fluid, they are promising biomarkers for the detection of disease.
Exosomes loading with drugs have been widely used for various diseases treatment. In a research, exosomes containing the anti-inflammatory small molecule compound curcumin have been shown to protect mice from brain inflammation induced by lipopolysaccharides. The incorporation of curcumin in exosomes improved its solubility, prolonged circulation time, retained drug therapy activity, and improved brain delivery. During tumor treatment, tumor exosomes loaded with anti-tumor drugs can effectively ensure drug maintain their native property and promote drug transport to target tumor tissue. This factor will drive the growth of market in the forecast period.
Exosomes are perceived to be used as carriers between different locations of body. Exosomes are secreted by all types of cells and are also found abundantly in the body fluids such as saliva, blood, urine and breast milk.
However, a number of technical difficulties need to be addressed for the successful implementation of exosomes in various applications, this factor will hamper the market during the forecast period. Some of the major difficulties include optimization of purification, increasing the homogeneity of exosomes, and efficient transfection strategies.
The recent outbreak of the COVID-19 pandemic is likely to act as a major restraint to market. Most diagnostic centers are busy in the COVID-19 test which will delay its therapeutics uses in the centers. This factor will hinder the growth of the market in the forecast period.
The global medical coding market is segmented based on application by cancer applications, and non-cancer applications. The cancer applications is further sub segmented into lung cancer, breast cancer, prostate cancer, colorectal cancer and others. Lungs cancer held the largest market share due to increasing prevalence of lung cancer. The need for more efficient diagnostic systems is due to the fact that only 15% of the lung cancer cases get diagnosed while the remaining undiagnosed cancer cases develop into more aggressive forms, which reduces the 5-year survival rate to only 4% in these patients that are detected with late-stage lung cancer.
According to Centers for Disease Control and Prevention (CDC), lung cancer is the primary cause of cancer death and the second most common cancer. According to American Cancer Society in U.S. approximately 195,000 people are suffering from lungs cancer every year and the mortality rate accounts for approximately 135,000.
Smoking, environmental pollution, environmental pollution, rising cases of infections, growing rates of early detection and awareness are the leading factor of lungs cancer and drives the growth of the segment in the forecast period.
The colorectal cancer segment is expected to have positive market growth in the forecast period. According to American Cancer Society, in United States when men and women are considered individually colorectal cancer is the third prominent cause of cancer-related mortality, and the second prominent cause when both are combined. Increasing adoption of western diet which are high in fat and low in fiber is expected to boost the growth of segment over the forecast period.
According to National Cancer Institute, in 2016, an estimated 134,490 people in the United States will be diagnosed with colorectal cancer and 49,190 people will die from it. Due to increase in screening of colorectal cancer and changes in some risk factors such as a decline in smoking and consumption of alcohol is decreasing the rate of new colorectal cancer cases and deaths among adults aged 50 years and above.
Further, the market is also classified based on end user as diagnostics, therapeutics, hospitals & clinical testing laboratories and others. The therapeutics segment is held the largest market share. Exosomes have promising potential to be as a vehicle for drug delivery as they have natural material transportation properties, the capability of intrinsic long-term circulation, and high biocompatibility, which are the most suitable factors for the delivery of a variety of proteins, chemicals, and nucleic acids. According to a few research studies, exosomes have generated positive results as mediators of the intercellular communication, potentially delivering the functional proteins, mRNA transcripts, and miRNAs to cells throughout the body.
Exosomes which are derived from some types of cells such as dendritic and mesenchymal stem cells have potential therapeutic properties and are biocompatible and efficient agents against various disorders such as organ injury. This factor will drive the growth of market in the forecast period.
By region, the exosomes market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global exosomes market and is expected to grow at the highest CAGR during the forecast period due to better healthcare infrastructure, effective government policies, a huge base of multinational companies, and high awareness among people about diagnostics and healthcare.
A large number of government-funded research studies have been conducted, regarding the role of drugs using exosomes in several kinds of cancers, such as melanoma, breast cancer, lung cancer, and pancreatic cancer, among others.
Companies, like Merck and Exosome Diagnostic, have sponsored and collaborated with several universities, such as Yale University and Michigan State University, to conduct clinical trials in the United States. Furthermore, these ventures are very well supported by government funding. These factors will drive the growth of market in the region.
For instance, in March 2017, researchers at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine received two grants from the Sohn Conference Foundation for R&D in isolation and characterization of tumor-derived exosomes to study cancer occurrence in children.
The Asia-Pacific region is expected to have third-largest share due to the higher growth rate is attributed to immense potential identified in emerging economies such as China and India. Competitive strategies adopted by players to carry out R&D activities in this sector. The growth of the various pharmaceutical companies in the region is also driving the growth of the market in the forecast period.
The exosomes market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, NX Pharmagen, Novus Biologicals, Qiagen, Thermo Fisher Scientific Inc. are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the exosomes across the globe.
For instance, in 2018, Thermo Fisher Scientific expanded its presence in the US by opening the U.S. Precision Medicine Science Center (PMSC) in Cambridge. This center is aimed to develop analytical workflows to generate precise molecular profiles of patients.
In 2018, Lonza established its Collaborative Innovation Center (CIC) in the new Life Science Park in the outskirts of Haifa, Israel. This center focuses on R&D projects of Lonza's Pharma & Biotech segment.